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Abstract  
This study investigated the osteoconductive properties of a porous hydroxyapatite (HA) scaffold 
manufactured using a novel technique similar to the bread-making process, alone and in combination 
with an alginate polysaccharide fibre gel (HA/APFG putty) and autologous bone marrow aspirate (BMA).  
The hypothesis was that the HA/APFG putty would be as osteoconductive as granular HA and that the 
presence of BMA would further enhance bone formation in an ovine femoral condyle critical defect model.   
 
Thirty-six defects were created and either (1) porous HA granules, (2) HA/APFG putty or (3) HA/APFG 
putty + BMA were implanted.  Following retrieval at 6 and 12 weeks, image analysis techniques were 
used to quantify bone apposition rates, new bone area, bone-HA scaffold contact and implant resorption.  
 
At 6 weeks post-surgery, significantly lower bone apposition rates were observed in the HA/APFG putty 
group when compared to the HA (p = 0.014) and HA/APFG putty + BMA (p = 0.014) groups.  At 12 
weeks, significantly increased amounts of new bone formation was measured within the HA scaffold 
(33.56 ± 3.53%) when compared to both the HA/APFG putty (16.69 ± 2.7%; p = 0.043) and defects 
containing HA/APFG putty + BMA (19.31 ± 3.8%; p = 0.043). 
 
The use of an alginate polysaccharide fibre gel as a carrier for injectable CaP bone substitute materials 
delayed bone formation in this model compared to HA granules alone which enhanced bone formation 
especially within the interconnected smaller pores.  Our results also showed that the addition of 
autologous bone marrow aspirate did not further enhance its osteoconductive properties.  Further work is 
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required to optimize the degradation rate of this alginate polysaccharide fibre gel binging agent before 
use as a directly injectable material used for bone defect repair. 
 
Keywords: Bone regeneration; calcium phosphate; bone marrow aspirate; bone substitute materials. 
 
Introduction 
Increases in reconstructive orthopaedic surgery resulting from advances in surgical practice and the 
ageing population have led to an increase in the use of bone substitute materials, especially in oncologic 
surgery, traumatology, revision prosthetic surgery and in spinal surgery (1).   Over two million bone 
grafting procedures are performed every year, and synthetic bone substitute materials are often used 
due to their ease of handling, excellent biocompatibility, improved safety profiles, low cost, availability 
and their ability to be used in a variety of clinical situations.  The purpose of a graft material is to 
augment bony regeneration within a defect where the new bone formed should ideally penetrate and 
replace the graft through sequential remodelling, enabling the repair site to maintain an optimal balance 
between form and function (2).  Currently, the "gold standard" in terms of bony integration is obtained 
using autograft due to its biological performance in terms of osteoinductivity (7 - 9) and osteoconductivity 
(9 – 11).  However disadvantages including limited availability and explant site pain and morbidity have 
reduced its use (5, 6).  Allografts and xenografts which are only osteoconductive, can overcome these 
limitations, but the risk of immune reactions and in some countries, limited availability of tissue banks, 
patient compliance and regulatory restrictions are at present, significant problems (12, 13).  Synthetic 
bone graft substitutes based on calcium phosphate materials are valid alternatives to tissue transplants 
and have been utilised clinically for over three decades, with varying efficacy and success (14).  A 
limitation with current CaP bone substitute materials is that they often exist in a dry granular form, 
limiting handling ability during surgery (3).  In the last 15 years, injectable and moldable forms of bone 
substitute material, such as pastes and putties, have been developed as they offer many advantages 
including increased handling ability and are able to completely fill contained defects of complex 
geometric shapes (4) In addition and with the development of minimally invasive surgical methods, the 
requirement to treat bony defects with directly injectable biomaterials is increasing (3).  The combination 
of hydrogels and calcium phosphate particles is emerging as a well-established trend for bone 
substitutes.  Hydrogels are macromolecular networks with high hydrophilicity and interconnections 
between the polymeric chains.  This structure allows them to swell without dissolution and although good 
cohesion between the hydrogel and CaP particles has been shown at the site of implantation, a balance 
with the viscosity is required as less viscous carriers are required for easier injectability.  However this 
low viscosity may have a negative effect on shelf stability causing settling and phase separation upon 
injection (13).  The degradation rate of the hydrogel matrix and the composite stiffness of the construct 
are both important as these factors have been shown to significantly influence vascularisation and cell 
influx within the biomaterial (13, 15-17).  A hydrogel that degrades too slowly, may delay cell colonization 
and impede new bone formation as the cells are unable to penetrate the CaP scaffold in an appropriate 
time scale. Bone marrow aspirate (BMA) is a source of pluripotent cells and its use in combination with 
HA and β-TCP bone substitute materials has been shown to have a significant effect on increasing bone 
regeneration within the scaffold (26 - 28). Although the number of stromal cells present within BMA are 
relatively low compared to treatments where these cells have been expanded in vitro, the direct use of 
BMA in augmenting bone healing avoids regulatory issues and is significantly less expensive (36). 
 
The aims of this study were two-fold.  The first aim was to investigate whether the addition of an alginate 
polysaccharide fibre gel binding agent will have an effect on the osteoconductive properties of a porous 
HA scaffold manufactured using a novel technique similar to the bread-making process.  The second aim 
was to investigate whether bone formation within a porous HA scaffold with binding agent, would be 
further augmented by the addition of autologous stromal and progenitor cells. The hypotheses of this 
study were that the HA/APFG putty biomaterial would be as osteoconductive as granular HA and that the 
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presence of BMA would further enhance the osteoconductive properties in an ovine femoral condyle 
critical defect model at 6 and 12 weeks.   
 
Materials and Methods 
Surgery 
A total of thirty-six cylindrical, critical sized defects measuring 8 × 15 mm were created in the medial 
condyle of both the left and right femur of nine skeletally mature commercially cross-bred adult female 
sheep weighing between 65 and 80 kg and aged between 2 and 5 years.  Three experimental groups 
were investigated at two time-points (6 and 12 weeks) post-operatively; (1) porous HA granules, (2) 
porous HA granules within an alginate polysaccharide fibre gel binding agent (HA/APFG putty) and (3) 
porous HA granules within an alginate polysaccharide fibre gel combined with autologous bone marrow 
aspirate (HA/APFG putty + BMA).  Positions were rotated such that no implant combination was placed 
in the same location in each sheep more than once.  All implants were provided sterile and pre-
packaged by Orthogem Ltd (Nottingham, UK) and this study investigated the osteoconductive properties 
of TriPore® HA (Orthogem Ltd, Nottingham, UK).  TriPore® is a phase pure hydroxyapatite (crystallinity > 
85%) with a multilayered interconnected porous architecture that mimics the natural composition of bone.  
TriPore® consists of a unique three pore structure consisting of interconnected macropores (100 – 800 
μm diameter), midipores (10 – 100 μm diameter) and microspaces (1 – 10 μm diameter)  (Figure 1).   
TriPore® has a total macroporosity of 80% and granules used in this study were irregularly shaped and 
measured between 2 - 4 mm in size.  The granule packing characteristics were not measured in this 
study.  The porosity in these granules was developed by a novel process whereby yeast was added to a 
mixture of carbon hydrate powder, HA powder and water to form a dough-like material. The porous 
structure in the scaffold was generated in a process similar to bread-making using a warm oven to make 
a green structure.  The porous materials were then fired up in a high temperature furnace to remove any 
carbon hydrate materials and organic matter in order to maintain the porous structure within the HA 
block. 
 
At the start of surgery, bone marrow aspirate was collected from the iliac crest and 1 ml of aspirate 
combined with each 1 cm3 of HA/APFG putty prior to implantation. The HA/APFG putty was prepared by 
mixing a ratio of 0.045 g alginate dry fibre with 1 cm3 of HA granules and 1 cm3 of water (Figure 2). The 
putty formed a gritty, viscous paste that was molded into the defects by slight pressure and remained in 
place without flow and migration from the defect. In the non-putty group and prior to implantation, HA 
granules were gently immersed and coagulated in 10 mls of venous blood to limit granule migration out 
of the defect.  Prior to insertion, each wound was irrigated with sterile saline and the appropriate test 
material gently pressed into place.  The location of each defect was marked by drilling and inserting two 
1 mm sized tantalum beads on either side within adjacent bone.   A second defect site was then created 
and separated by at least 1 cm of bone before the wound was closed and the procedure repeated on the 
contralateral side.   Two implants were inserted into each femoral condyle and a total of four inserted into 
each animal. This means that at least one implant was repeated twice in each animal.  This was not 
necessarily always the control, however every animal had a control defect present.  Repeats of 6 
implants per group at each of the 6 and 12 week time-points were investigated.  All procedures were 
carried out following Ethics approval granted by the Royal Veterinary College and in compliance with the 
United Kingdom Home Office regulations [Animal Scientific Procedures Act (1986)]. Following surgery, 
animals were allowed immediate and full mobilization as tolerated.  Antibiotic and analgesic prophylaxis 
was administered daily with subcutaneous injections of Baytril (Enrofloxacin 5 mg/kg; Bayer AG 
Leverkusen) and Finadyne (Flunixin Meglumine 2 mg/45 kg; Schering-Plough) for 3 days post-surgery.  
Animals were kept in individual pens for 1 week post operatively before being group housed.  Two 
fluorochrome bone markers Oxytetracyline (30 mg/kg) and Calcein Green (30 mg/kg) were administered 
at weeks 2 and 4 in the six week group, and 8 and 10 weeks in the twelve week group.  Oxytetracylcine 
and Calcein Green localize at sites of mineralization and when viewed under ultra-violet light, fluoresce 
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an orange and green colour respectively.  The mean measurable distance between cement lines 
provides an assessment of bone apposition rates (μm /day) within defects in each of the groups.  
 
On retrieval, condyles were placed in 4% paraformaldehyde solution before being processed for 
undecalcified histology. Following dehydration in serial dilutions of alcohol, specimens were defatted and 
embedded in hard grade acrylic resin (LR White, London Resin Company, Reading, UK).  Radiographs 
were taken and the location of each defect identified by the position of adjacent tantalum beads.  Thin 
sections  (~ 70 µm) were prepared by making longitudinal cuts through the centre of each defect using a 
grinding and polishing technique (EXAKT, Norderstedt, Germany).  Samples were stained with Toluidine 
Blue and Paragon, which stained the soft tissue and bone respectively. In each of the three experimental 
groups investigated, total new bone area, bone-HA scaffold contact and scaffold resorption were 
quantified.  Six random regions of interest (ROI) were image captured using a 5×-magnification lens 
where three ROIs were located at the periphery and three within the centre of each defect site 
(Axiovision Release 4.6, Carl Zeiss, Jena, Germany). The line intercept method was used and a mask of 
interconnecting lines measuring 10 × 12 mm was superimposed on top of each image and the type of 
material (mineralised bone, soft tissue or scaffold) at the intersection of each line was determined (total 
of 225 intercept points per image). Assessments were made to evaluate the proportion of mineralised 
bone formed, soft tissue and implant material within each of the 6 regions in each defect.  The 
percentage of bone ingrowth is a percentage of the total area of the substitute material and not the just 
the available area for ingrowth.  For bone-HA scaffold contact, the type of tissue at the interface was 
determined at the points where lines intersected with the biomaterial surface. The size of the pores was 
measured using image analysis.  Quantification of bone in pores > 10μm was measured using the line-
intercept technique and expressed as a percentage, however bone within pores < 10 µm was not 
measured as these sized pores occurred predominantly within the struts of the scaffolds.  Data was 
quantified and compared between groups.    
 
Scanning Electron Microscopy 
Thin sections were sputter-coated with a layer of gold palladium and viewed using Backscattered 
electron microscopy (JOEL JSM-5500LV; Jeol, Welwyn Garden City, UK).  
 
Statistical Analysis 
Analysis of the data was performed using SPSS software (v10.1; SPSS, Chicago, Illinios).  A 
Kolmogorov-Smirnov test showed the data obtained was non parametric and the Mann-Whitney U test 
was used for statistical comparison between experimental groups.  The Kruskal-Wallis test with post-hoc 
Mann Whitney U was used to compare data at different time points within one experimental group. p 
values < 0.05 were considered significant. 
 
Results 
Bone Apposition Rates 
At 6 weeks post surgery, the slowest rate of bone apposition was measured in the HA/APFG putty group 
where no bone turnover was observed in any of the specimens (Figure 3).  Apposition rates where 
higher in the HA (1.18 ± 0.68 m/day) and HA/APFG + BMA (0.53 ± 0.53 m/day) groups however no 
significant differences between these three groups were found.  In all groups and at 12 weeks post 
operatively, bony apposition rates had significantly increased when compared to the HA/APFG putty 
group at the 6 week time point; HA (1.40 ± 0.13 m/day; p = 0.011), HA/APFG + BMA (1.53 ± 0.19 
m/day; p = 0.011) and HA/APFG putty (1.28 ± 0.11 m/day; p = 0.008).  No other significant differences 
were found when rates were compared at the 6 and 12 week time points.  
 
New Bone Area 
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At 6 weeks post surgery, highest amounts of new bone formation was measured within the HA granule 
group (18.30 ± 5.06%) with least new bone measured within HA/APFG + BMA scaffolds (8.57 ± 2.90%), 
however no significant differences between groups was found (Figure 4).  By 12 weeks, the amount of 
new bone formed had significantly increased in the HA (33.32 ± 2.74%; p = 0.05) and HA/APFG putty + 
BMA (19.32 ± 2.30%; p = 0.027) groups when compared to the 6 week time-point.  Significantly highest 
amounts of new bone was measured in the HA granule scaffolds when compared to both the HA/APFG 
putty (18.05 ± 2.91%; p = 0.018) and HA/APFG putty + BMA (p = 0.016) scaffolds.   
 
Bone-HA Scaffold Contact 
At 6 weeks post surgery, highest amounts of bone-HA contact was measured in the HA granule group 
(59.34 ± 10.89%).   Lowest values were seen in the HA/APFG putty + BMA group (25.99 ± 7.46%) 
(Figure 5).  However, no significant differences were found.  At 12 weeks post operatively, bone-HA 
scaffold contact had increased in all three groups, however a statistically significant increase was only 
seen in the HA/APFG putty + BMA group (p = 0.027).  Significantly highest amounts of bone-HA scaffold 
contact was measured in the HA granule group (72.65 ± 3.38%) when compared to both the HA/APFG 
putty (52.66 ± 4.30%; p = 0.018) and HA/APFG putty + BMA groups (54.01 ± 6.31%; p = 0.047).   
 
Implant Area 
No significant differences were found when implant resorption was compared in the three groups over 
the 6 and 12 week post operative period (Figure 6).  
 
Qualitative Analysis 
Analysis using light microscopy showed that new bone formation had occurred in all groups at the 6 
week time-point post surgery (Figure 7). Qualitatively, there appeared to be little difference in the way 
that the bone and soft tissue reacted to the different compositions.  In all specimens, bone was closely 
associated with the Tripore® granule surface and appeared to form in a similar manner through 
intramembranous ossification.  Bone formation was associated initially with the deposition of collagen 
fibres, often organized perpendicular to the implant and bone forming surface.  These collagen fibres 
were 5 – 10 m in diameter.  In all groups, bone formation was associated predominantly with the 
concentric walls of the pores and then filled the pore in a centripetal manner.  
 
At 12 weeks, and in most specimens in the HA/APFG putty and HA/APFG putty + BMA groups, residual 
carrier was evident within the intergranular spaces (Figure 8).  Samples in both groups showed no signs 
of an inflammatory reaction at either of the time-points investigated.  Overall, increased amounts of bone 
formation was seen adjacent to the Tripore® granule only group however in all groups, mature lamellar 
bone was observed bridging granules together.   Light microscopy showed areas of vascularization in all 
groups at both time-points with blood vessels evident both adjacent to the HA granules and within the 
pore structure.  No obvious differences in the amount of vascularization was seen when all groups were 
compared at the same time point. Backscattered scanning electron microscopy showed that at both the 
6 and 12 week time points and in all groups, bone formation was seen in pores as small as 10 µm in size 
(Figure 9).  Occasionally and in localized regions and with all three implant types, debris associated with 
fragmentation of the HA scaffold was observed within macrophages and multinucleate cells found close 
to the surface of the implant.     
 
Discussion 
A disadvantage in the use of many of the current calcium phosphate based bone substitute materials is 
that they exist as a hard and brittle material that is difficult to mold into the desired defect shape.  During 
surgery, this often requires the surgeon to reshape the surgical site around the shape and structure of 
the implant causing an increase in bone loss, trauma to the surrounding tissue and longer surgical time 
(18).  In addition, filling bone voids with individual particles may lead to incomplete filling of the defect or 
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granule dispersion and loss during surgery.  Using flowable or moldable pastes or putties in which the 
binder or gel is added to the calcium phosphate ceramic granules, offers several clinical and economical 
advantages including the use of minimally invasive techniques where directly injectable materials may 
allow complete filling of the defect site thereby avoiding voids which can lead to fibrous encapsulation 
(19).  Adding a polymer binder to osteoconductive calcium phosphate ceramic would appear the method 
of choice, but this may be detrimental to its osteoconductive potential.  The aim of this study was to 
investigate the use of an injectable calcium phosphate bone graft material combined within an alginate 
polysaccharide fibre gel carrier.  A commercially available porous HA scaffold (Tripore® Nottingham, UK) 
was combined with an alginate polysaccharide fibre gel and bone formation within the scaffold 
compared to and without autologous bone marrow within critical sized defects in an ovine model.   The 
critical sized bone defect is defined as the smallest sized osseous wound that will not spontaneously 
heal with bone tissue (20).  In the ovine model, a defect size of 8 × 15 mm is considered critical (21, 23) 
and these defects have been successfully used for the placement of materials in the evaluation of the 
bone healing response to bone substitutes (21 – 23).   
 
A hydrogel carrier may improve surgical handling, allow direct delivery into the defect site and maintain 
graft placement, however it must be biocompatible with both the surrounding tissue, provide a suitable 
environment for bone regeneration and must not interfere with the bone healing mechanism.  Optimal 
carriers should resorb within the first few days of implantation otherwise its presence may interfere with 
the initial bone healing phase by impeding cell influx, the interaction of connective tissue, vascularisation 
within the HA intergranular space and fast bone growth (3, 13, 33).   Turner et al. (29) investigated the 
use of three formulations of injectable calcium sulphate-based putties containing deminseralised bone 
matrix and a hydroxypropylmethylcellulose binding agent.  Results showed greater amounts of bone 
formation when compared to control defects and they concluded that the putties investigated were an 
effective delivery means for bone graft materials in bony defect repair.  Another study by Turner et al. (30) 
investigated bone regeneration in a canine critical size defect model and showed that the same putty 
was as effective as autograft in healing bone at 6, 13 and 26 weeks post surgery.  A study by Urban et al. 
(31) also reported successful bone healing with calcium sulphate-based materials within a 
hydroxypropylmethyl cellulose carrier in a canine model at 13 and 26 weeks post operatively.  In contrast, 
an in vitro study reported by Sohier et al. (32) investigated the use of a silated hydroxypropylmethyl 
cellulose hydrogel as a carrier for calcium phosphate ceramics and showed that following three 
dimensional culture, human bone marrow derived mesenchymal stem cells remained viable and retained 
their osteoblastic differentiation potential, however were not able to proliferate or colonise the constructs.  
They concluded that the hydrogel was not suitable for bone tissue engineering as the gel did not present 
a micro-environment with any recognisable binding sites allowing cells to attach, migrate and proliferate.  
The same group compared crosslinked and non-crosslinked formulations of the carrier in a critical size 
femoral epiphysis defect in rabbits, and concluded that the carrier delayed cell colonisation and new 
bone formation (33).  They suggested that this was because the carrier degraded too slowly, impeding 
cell penetration into the construct within an appropriate time-scale, as shown in their in vitro study, even 
though the carrier degraded without release of cytotoxic products (34).   A similar outcome was recently 
reported in an ectopic bone formation ovine model where five different hydrogels were investigated as 
carriers for calcium phosphate bone substitute materials.  They reported a general trend where bone 
formation increased into the gaps between the CaP granules in carriers that dissolved faster (35).  These 
studies suggest that an inert chemistry, rapid dissolution and clearance of the polymer binder 
surrounding the microarchitecture of the CaP granules is required to allow for optimal bone formation.   
 
In our study, bone apposition rates, percentage new bone area and bone-HA scaffold contact increased 
in all groups at the 12-week time-point when compared to 6 weeks post operatively.   A study by Hing et 
al. (24) investigated bone apposition rates and bone formation within porous HA granules (without a 
carrier) in a bony defect in rabbits at 3, 12 and 24 weeks. Results showed an increased rate of bone 
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mineralisation with increasing time post-operatively.  The authors suggested that the difference maybe 
due to blood vessel infiltration within the graft area and increased protein adsorption to the scaffold.  
Bone formation begins with the formation of an apatite layer which enhances protein adsorption resulting 
in the differentiation of osteoprogenitor cells into osteoblasts leading to the deposition of bone (25).  In 
order for the apatite layer to form, the bone graft material must first come into contact with blood, which 
facilitates the dissolution of the graft and its re-precipitation onto the surface (14, 24, 25).  In addition, 
blood is an abundant source of proteins, which would further enhance this process.  Qualitative results 
from our study showed fewer areas of blood vessel formation in the 6 week groups when compared to 
samples at 12 weeks post surgery and this may be the reason why a significantly reduced bone 
apposition rate, new bone area and bone-HA scaffold contact was measured early on.  In addition, bone 
apposition rates, percentage new bone area and bone-HA scaffold contact were all significantly 
decreased in the HA/APFG putty and HA/APFG putty + BMA groups at both of the time points 
investigated, and it is likely that the gel carrier present within the defects impeded connective tissue 
infiltration, angiogenesis and new bone formation.  Increased bone area was measured in the two putty 
groups as the post-operative time increased, and it is possible that gradual degradation of the gel 
allowed increasing exposure of the HA scaffold to connective tissue penetration, angiogenesis and new 
bone formation.  However, bone formation was significantly lower than with the granules alone, and this 
is because the putty had not completely resorbed and had prevented bone formation within the pores.   
 
Our study showed that tissue within the pores < 10 micron in size was mineralised collagen.  This is a 
remarkable observation because these pores are too small for osteoblasts.  Yet, mineralised bone was 
present and we believe that this may have been associated with the flow of osteoid and the formation of 
collagen before mineralisation into the pores from nearby cells.  
 
Bone marrow aspirate contains pluripotent mesenchymal stem cells and has been shown to have a 
significant effect on increasing bony healing within HA and β-TCP bone substitute materials to rates 
similar to autograft (26 - 28).  In our study, the incorporation of autologous BMA within the scaffold 
material was used to provide a source of stem cells and growth factors thereby potentially increasing the 
rate and amount of new bone formation.  Results showed that the alginate polysaccharide fibre gel 
significantly inhibited new bone formation and bone-HA scaffold contact despite the presence of bone 
marrow within the defect.   
 
In this study, we hypothesised that the HA/APFG putty would be as osteoconductive as granular HA and 
that the presence of BMA would further enhance bone formation in an ovine femoral condyle critical 
defect model.  Results showed that the presence of the gel significantly impeded new bone formation 
and bone-HA scaffold contact and we can therefore reject our hypothesis.  Limitations of this study were 
that the resorbablity of the APFG carrier was not quantified and the effect of BMA on augmenting bone 
growth within the porous HA granules without the gel was not investigated. Another criticism may be the 
low number of animals used, but we found statistical differences in both bone area and bone contact 
which were two of the three parameters measured in this study.  A reasonable increase in the number of 
animals would not have shown any differences in bone apposition rates between the various groups as 
the p value was high. 
The delayed bone formation response seen in this study is important when considering the use of a putty 
for the injectable delivery of calcium phosphate granules in bone defect repair and a balance between 
handle ability during surgery, mechanical stability and cell influx needs to be further optimised.  New 
putties and injectables used for the administration of bone substitute materials should be tested in vivo in 
an effective model and results from bone grafts incorporated within putties should be similar to bone 
formation in granules without the use of a carrier. 
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Figure Legends 
Figure 1   
Electronmicrographs showing [A] the interconnected macroporous structure, [B] midipores and [C] 
microspaces among the annealed ceramic particles. 
 
 
 
Figure 2   
A photograph showing [A] the porous HA granules, [B] the HA APFG putty and [C] a critical sized defect 
made within the medial femoral condyle. 
 
Figure 3  
Bone Apposition Rates (μm /day) in all experimental groups at 6 and 12 weeks post surgery. 
 
Figure 4   
Percentage New Bone Formation within each of the three scaffolds at the 6 and 12 week post-operative 
time-points. 
 
Figure 5  
Percentage Bone-HA Scaffold contact within each of the three scaffolds at the 6 and 12 week post-
operative time-points. 
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Figure 6 
Percentage implant resorption over time. 
 
Figure 7  
Micrographs showing bone formation within HA scaffolds [A] + [C], the HA/APFG putty scaffold [B] and in 
[D], the HA/APFG putty + BMA group at 6 weeks post surgery. 
 
Figure 8  
Micrographs showing bone formation within HA scaffolds [A] + [C], the HA/APFG putty scaffold [B] and in 
[D], the HA/APFG putty + BMA group at 12 weeks post surgery. 
 
Figure 9  
Electronmicrographs showing bone formation within HA scaffolds at 12 weeks post surgery.  The arrows 
point to bone formation within very small pores (< 10 µm). 
 
 
